GPT and cholestasis: Regarding hepatic function, enzymes of cytolysis (AST and ALT) and cholestasis (ALP) did not show significant variations when cetuximab was introduced as an experimental variable, indicating that its administration with the purpose of inhibiting tumor tissue did not cause additional damage to hepatic tissue.